These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 1815066)

  • 1. Prediction of the disposition of propafenone in humans and dogs from pharmacokinetic parameters in other animal species.
    Puigdemont A; Guitart R; de Mora F; Arboix M
    J Pharm Sci; 1991 Dec; 80(12):1106-9. PubMed ID: 1815066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Species scaling of propafenone disposition and concentration--time relationships among eight mammalian species.
    Puigdemont A; Ramis J; Guitart R; Arboix M
    J Pharm Sci; 1993 Nov; 82(11):1126-9. PubMed ID: 8289126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In-vitro plasma protein binding of propafenone and protein profile in eight mammalian species.
    Puigdemont A; Arboix M; Gaspari F; Bortolotti A; Bonati M
    Res Commun Chem Pathol Pharmacol; 1989 Jun; 64(3):435-40. PubMed ID: 2781140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phencyclidine pharmacokinetic scaling among species.
    Owens SM; Hardwick WC; Blackall D
    J Pharmacol Exp Ther; 1987 Jul; 242(1):96-101. PubMed ID: 3612541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Propafenone kinetics in the horse. Comparative analysis of compartmental and noncompartmental models.
    Puigdemont A; Riu JL; Guitart R; Arboix M
    J Pharmacol Methods; 1990 Apr; 23(2):79-85. PubMed ID: 2332982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mixed-effects modeling of the interspecies pharmacokinetic scaling of oxytetracycline.
    Martín-Jiménez T; Riviere JE
    J Pharm Sci; 2002 Feb; 91(2):331-41. PubMed ID: 11835193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic and toxicity scaling of the antitumor agents amsacrine and CI-921, a new analogue, in mice, rats, rabbits, dogs, and humans.
    Paxton JW; Kim SN; Whitfield LR
    Cancer Res; 1990 May; 50(9):2692-7. PubMed ID: 2328494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accuracy of allometrically predicted pharmacokinetic parameters in humans: role of species selection.
    Tang H; Mayersohn M
    Drug Metab Dispos; 2005 Sep; 33(9):1288-93. PubMed ID: 15919852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonlinear pharmacokinetics of propafenone in rats and humans: application of a substrate depletion assay using hepatocytes for assessment of nonlinearity.
    Komura H; Iwaki M
    Drug Metab Dispos; 2005 Jun; 33(6):726-32. PubMed ID: 15743979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue distribution of propafenone in the rat after intravenous administration.
    Fernández J; Lligoña L; Puigdemont A; Guitart R; Riu JL; Arboix M
    Eur J Drug Metab Pharmacokinet; 1991; 16(1):23-7. PubMed ID: 1936057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-invasive and quantitative evaluation of post-injection muscle damage by pharmacokinetic analysis of creatine kinase release.
    Lefebvre HP; Laroute V; Braun JP; Lassourd V; Toutain PL
    Vet Res; 1996; 27(4-5):343-61. PubMed ID: 8822606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereoselective disposition and pharmacologic activity of propafenone enantiomers.
    Kroemer HK; Funck-Brentano C; Silberstein DJ; Wood AJ; Eichelbaum M; Woosley RL; Roden DM
    Circulation; 1989 May; 79(5):1068-76. PubMed ID: 2713973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacokinetic and pharmacodynamic interaction between propafenone and lidocaine.
    Ujhelyi MR; O'Rangers EA; Fan C; Kluger J; Pharand C; Chow MS
    Clin Pharmacol Ther; 1993 Jan; 53(1):38-48. PubMed ID: 8422740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic and pharmacodynamic interaction between mexiletine and propafenone in human beings.
    Labbé L; O'Hara G; Lefebvre M; Lessard E; Gilbert M; Adedoyin A; Champagne J; Hamelin B; Turgeon J
    Clin Pharmacol Ther; 2000 Jul; 68(1):44-57. PubMed ID: 10945315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allometric scaling of orbifloxacin disposition in nine mammal species: a retrospective analysis.
    Gebru E; Lee SJ; Kim JC; Park SC
    J Vet Med Sci; 2011 Jun; 73(6):817-20. PubMed ID: 21233597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of clearance, volume of distribution and half-life by allometric scaling and by use of plasma concentrations predicted from pharmacokinetic constants: a comparative study.
    Mahmood I
    J Pharm Pharmacol; 1999 Aug; 51(8):905-10. PubMed ID: 10504028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of human pharmacokinetics of panipenem, a new carbapenem antibiotic, from animal data.
    Nakashima M; Kurihara A; Hisaoka M
    Drugs Exp Clin Res; 1992; 18(9):371-5. PubMed ID: 1299587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the pharmacodynamic effects of intravenous and oral propafenone.
    Haefeli EW; Vozeh S; Ha HR; Follath F
    Clin Pharmacol Ther; 1990 Sep; 48(3):245-54. PubMed ID: 2401123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolism of propafenone and verapamil by cryopreserved human, rat, mouse and dog hepatocytes: comparison with metabolism in vivo.
    Reder-Hilz B; Ullrich M; Ringel M; Hewitt N; Utesch D; Oesch F; Hengstler JG
    Naunyn Schmiedebergs Arch Pharmacol; 2004 Apr; 369(4):408-17. PubMed ID: 14999438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative pharmacokinetics of enrofloxacin in mice, rats, rabbits, sheep, and cows.
    Bregante MA; Saez P; Aramayona JJ; Fraile L; Garcia MA; Solans C
    Am J Vet Res; 1999 Sep; 60(9):1111-6. PubMed ID: 10490081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.